Connecticut is currently home to 1248 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Hamden, Connecticut
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
Assessing the Effectiveness of Digital Wellness Modules on Perceived Quality of Life
NCT05810259
Recruiting
The study will examine the role of digital wellness modules (brief mindfulness and light to moderate physical exercise) delivered through a smartphone wellness application and their short-term effects on health behavior motivation and change, and longer-term quality of life and non-pathological affective states.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/13/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Wellness, Quality of Life, Anxiety, Depression
Register for Updates
Identifying and Characterizing Preclinical MS
NCT05787795
Recruiting
The purpose of this research study is to try and identify risk factors and biologic changes that suggest that someone may go on to develop multiple sclerosis before a person has shown any symptoms of the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Yale University, North Haven, Connecticut
Conditions: Multiple Sclerosis
Register for Updates
Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)
NCT05377840
Recruiting
This is a prospective, single center, randomized treatment study to assess if anxiety and depression in participants with IBD can be improved with CBT compared to those treated with SKY.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Crohn Disease, Ulcerative Colitis (UC)
Register for Updates
DBT Skills Groups for Veterans at High Risk for Suicide Attempt
NCT05000749
Recruiting
Veteran suicide death is a national crisis. Risk factors include emotion dysregulation, which occurs across mental health disorders. Dialectical behavior therapy (DBT) is an evidence-based suicide intervention that targets emotion dysregulation but is resource-intensive and not widely available at VHA. A more efficient evidence-based DBT Skills Group (DBT-SG) is associated with reduced suicidal ideation and emotion dysregulation and likely more feasible to implement at VHA. This is a randomized... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
Conditions: Suicide, Attempted
Register for Updates
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects with Myasthenia Gravis
NCT06106672
Recruiting
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/12/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Register for Updates
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
NCT05974150
Recruiting
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Register for Updates
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430
Recruiting
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Solid Tumor, Adult, Refractory Cancer, Cutaneous Melanoma, Non-small Cell Lung Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, PMMR/MSS Adenocarcinoma of the Colon or Rectum
Register for Updates
Generic Database of Very Low Birth Weight Infants
NCT00063063
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Follow-up Visit of High Risk Infants
NCT00009633
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
NCT06196203
Recruiting
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Yale Cancer Center, New Haven, Connecticut
Conditions: Higher-risk Myelodysplastic Syndromes
Register for Updates
Measuring Brain Health Using Low-Field Portable MRI
NCT06533631
Recruiting
The purpose of this study is to develop a new grading scale and utilize automated segmentation for measurement of White Matter Hyperintensity (WMH) volume using a low field MRI.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/07/2025
Locations: Yale Magnetic Resonance Research Center (MRRC) at The Analyn Center (TAC), New Haven, Connecticut
Conditions: White Matter Hyperintensity
Register for Updates